307 related articles for article (PubMed ID: 21402518)
1. Can a pharmacist reduce annual costs for Medicare Part D enrollees?
Alston G; Hanrahan C
Consult Pharm; 2011 Mar; 26(3):182-9. PubMed ID: 21402518
[TBL] [Abstract][Full Text] [Related]
2. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
3. Impact of Medicare Part D on independent and chain community pharmacies in rural Illinois--A qualitative study.
Bono JD; Crawford SY
Res Social Adm Pharm; 2010 Jun; 6(2):110-20. PubMed ID: 20511110
[TBL] [Abstract][Full Text] [Related]
4. Understanding the effects of Medicare Part D from key stakeholders' perspectives: Important progress, but abundant research opportunities remain.
Urmie JM; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):85-9. PubMed ID: 20511107
[No Abstract] [Full Text] [Related]
5. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
[TBL] [Abstract][Full Text] [Related]
6. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
7. Assessing the impact of coverage gaps in the Medicare Part D drug benefit.
Hudson N
Find Brief; 2008 Apr; 11(3):1-3. PubMed ID: 18441611
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
[No Abstract] [Full Text] [Related]
9. Pharmaceuticals and medical devices: Medicare Part D.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403844
[No Abstract] [Full Text] [Related]
10. Examining the impact of Part D on nursing home residents.
Hudson N
Find Brief; 2010 May; 13(4):1-3. PubMed ID: 21121179
[TBL] [Abstract][Full Text] [Related]
11. Medicare Part D: selected issues for plan sponsors, pharmacists, and beneficiaries in 2009.
Stubbings J; DePue RJ
Am J Manag Care; 2009 Sep; 15(9):645-9. PubMed ID: 19747029
[TBL] [Abstract][Full Text] [Related]
12. Promoting access and reducing expected out-of-pocket prescription drug costs for vulnerable Medicare beneficiaries: a pharmacist-directed model.
Cutler TW; Stebbins MR; Smith AR; Patel RA; Lipton HL
Med Care; 2011 Apr; 49(4):343-7. PubMed ID: 21407030
[TBL] [Abstract][Full Text] [Related]
13. 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina.
Sengupta S
N C Med J; 2008; 69(1):6-13. PubMed ID: 18429558
[TBL] [Abstract][Full Text] [Related]
14. Specialty pharmacy management will become more intense.
Collins S
Manag Care; 2010 Oct; 19(10):20-3. PubMed ID: 21049783
[No Abstract] [Full Text] [Related]
15. PDPs see increases in cost-sharing amounts.
Manag Care; 2009 Aug; 18(8):55. PubMed ID: 19731513
[No Abstract] [Full Text] [Related]
16. Assessment of drug consumption patterns for Medicare Part D patients.
Pedan A; Lu J; Varasteh LT
Am J Manag Care; 2009 May; 15(5):323-7. PubMed ID: 19435400
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
[No Abstract] [Full Text] [Related]
18. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
19. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
Bazalo G; Weiss RC
Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
Duggan M; Morton FS
Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975
[No Abstract] [Full Text] [Related]
[Next] [New Search]
